Copyright © 2002 by the European Society of Cardiology.
Cost-effectiveness of an invasive strategy in unstable coronary artery disease. Results from the FRISC II invasive trial
a Institution of Medicine and Care, Linköping University, Sweden
b Center for Medical Technology Assessment, Linköping University, Sweden
Received March 9, 2001; accepted March 21, 2001
Abstract
Aims The utilization and timing of revascularization in unstable coronary artery disease varies, which could have important consequences for patients and for treatment costs. The FRISC II invasive trial compared an early invasive strategy vs a non-invasive strategy with respect to the composite end-point of death and myocardial infarction as well as costs.
Methods and Results A total of 2457 patients, median age 66 years, comprising 70% men, were randomized. We prospectively recorded the patients' use of the health service. The results were analysed in a societal perspective. There was a significant 1·7% absolute reduction in deaths and a 3·7% absolute reduction in deaths and myocardial infarctions in the invasive compared to the non-invasive group after 12 months. During the initial hospitalization a patient in the invasive group spent on average 3·9 more days in hospital than a patient in the non-invasive group. Opposite results were found for rehospitalizations. The difference in mean total costs is SEK 23 876 (P<0·001). The incermental cost-effective ratio for choosing the invasive instead of the non-invasive strategy is SEK 1 404 000 per avoided death and SEK 645 000 per avoided death or myocardial infarction
Conclusion The high cost at the beginning of the invasive strategy is substantial. The clinical results of the FRISC II study provided evidence that the invasive strategy reduces the rate of death and myocardial infarction in patients with unstable coronary artery disease. For policy discussions concerning whether or not to implement the invasive strategy, these positive results should be balanced against the cost-consequences of the strategy.
Key Words: Unstable angina, non-Q wave myocardial infarction, unstable coronary artery disease, costs, cost-effectiveness, revascularization
f1 Correspondence: Magnus Janzon, MD, Department of Cardiology, Linköping Heart Center, University Hospital, SE-581 85 Linköping, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M Henriksson, D M Epstein, S J Palmer, M J Sculpher, T C Clayton, S J Pocock, R A Henderson, M J Buxton, and K A A Fox The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial Heart, June 1, 2008; 94(6): 717 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Perk and K. Alexanderson Chapter 8. Sick leave due to coronary artery disease or stroke Scand J Public Health, October 1, 2004; 32(63_suppl): 181 - 206. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Prasad, V. Mathew, D. R Holmes Jr., and B. J Gersh Current management of non-ST-segment-elevation acute coronary syndrome: reconciling the results of randomized controlled trials Eur. Heart J., September 1, 2003; 24(17): 1544 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Barrabes, J. Figueras, C. Moure, J. Cortadellas, and J. Soler-Soler Prognostic Value of Lead aVR in Patients With a First Non-ST-Segment Elevation Acute Myocardial Infarction Circulation, August 19, 2003; 108(7): 814 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Janzon, L-A Levin, and E Swahn Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial Heart, March 1, 2003; 89(3): 287 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Mahoney, C. T. Jurkovitz, H. Chu, E. R. Becker, S. Culler, A. S. Kosinski, D. H. Robertson, C. Alexander, S. Nag, J. R. Cook, et al. Cost and Cost-effectiveness of an Early Invasive vs Conservative Strategy for the Treatment of Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction JAMA, October 16, 2002; 288(15): 1851 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Moller Comment concerning 'Cost-effectiveness of an invasive strategy in unstable coronary artery disease' Eur. Heart J., October 2, 2002; 23(20): 1634 - 1634. [Full Text] [PDF]
|
|
|
|
 |
|
 Invasive Strategy for Non-ST-Segment Elevation MI Is Better but Costly Journal Watch Emergency Medicine, February 27, 2002; 2002(227): 9 - 9. [Full Text]
|
|
|
|
|
|
A.P. Davie and J.J.V. McMurray Cost effectiveness of invasive strategy in unstable coronary disease--what are we waiting for? Eur. Heart J., January 1, 2002; 23(1): 1 - 3. [Full Text] [PDF]
|
|